Purine biosynthetic and salvage pathway enzymes

The purine biosynthetic and salvage pathways are essential metabolic routes responsible for providing the cell with adenine and guanine nucleotides required for DNA and RNA synthesis, energy transfer (ATP/GTP), and signaling (StatPearls: Purine Metabolism, 2023). The de novo pathway constructs the purine ring from simple precursors like amino acids and CO2, while the salvage pathway recycles free purine bases through enzymes such as hypoxanthine-guanine phosphoribosyltransferase (HGPRT) (NCBI: Purine Biosynthesis, 2022). These enzymes are critical therapeutic targets in oncology and immunology because rapidly dividing cells, such as cancer cells and activated lymphocytes, have a high demand for nucleotides to support proliferation. Drugs targeting these pathways, such as thiopurines (e.g., 6-mercaptopurine) and folate antagonists (e.g., methotrexate), act as antimetabolites that disrupt nucleotide balance, ultimately leading to cell cycle arrest and apoptosis (PubChem: Methotrexate, 2024). Additionally, inhibitors of the salvage or degradation pathways, like allopurinol, are used to manage conditions like gout by reducing uric acid production (NIH: Allopurinol, 2023).

Other names

Purine metabolism enzymesPurine nucleotide synthesis pathwayDe novo purine biosynthesisPurine salvage pathway

Competitive or non-competitive inhibition of rate-limiting enzymes (e.g., IMPDH, DHFR) or incorporation of antimetabolites into DNA/RNA to cause chain termination or mismatch, leading to depletion of nucleotide pools and inhibition of nucleic acid synthesis.